25 results about "Joint synovium" patented technology

The present application belongs to the technical field of medicine, and particularly relates to the use of tetrahydrojatrorrhizine or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating rheumatoid arthritis. Experimental results show that tetrahydrojatrorrhizine can effectively alleviate the foot swelling level of CIA rats, reduce the arthritis score, and inhibit the progression of rheumatoid arthritis. Blood routine analysis shows that the administration of tetrahydrojatrorrhizine reduces the number of immune cells in the blood and weakens the immune level of the body. In addition, the experimental results also show that tetrahydrojatrorrhizine can inhibit synovial hyperplasia and relieve joint damage. Therefore, tetrahydrojatrorrhizine has the prospect of being developed into an oral medicament for treating rheumatoid arthritis, provides more treatment options for clinically treating rheumatoid arthritis, and has important social and economic values.

The invention relates to the technical field of arthritis treatment jackets, in particular to a rheumatoid arthritis hand auxiliary treatment jacket which comprises a glove, the glove is divided into a palm face and a hand back face, a wrist is constructed on one side of the glove, and a pressure control piece is arranged on the glove; the pressure control part comprises a cavity constructed in the glove, the cavity divides the glove into an outer layer and an inner layer, the outer layer is made of a heat preservation material, and the inner layer is made of an elastic material; a water injection valve communicated with the cavity is arranged on the glove, and liquid is allowed to enter and exit from the cavity by opening and closing the water injection valve; the three pressure control modes of wrist air bag pressurization and hand movement dynamic pressurization are adjusted through the liquid medicine injection amount, a patient can autonomously select pressure gears according to the illness state and the scene, low-gear mild pressurization is conducted during daily office mild movement, slight aching pain is relieved, operation is not affected, middle-gear moderate pressurization is conducted when joint swelling pain is aggravated, and therefore the patient can feel more comfortable. During night rest, middle and low gears can be flexibly selected, and morning stiffness is relieved while constraint feeling is avoided.

The application belongs to the technical field of natural medicinal chemistry, and relates to the use of a dibenzazepine compound in mistletoe in the preparation of a medicine for preventing or treating rheumatoid arthritis. In vitro experiments show that the use of the compound alone has different degrees of inhibitory effect on the proliferation of primary rat synovial fibroblasts, and the inhibitory effect is synergistically enhanced when the compound 2 is used in combination with mistletoe lectin. Animal experiments show that the use of the compound alone has different degrees of inhibitory effect on the joint swelling of a collagen-induced rat arthritis model, and the inhibitory effect of some dibenzazepine compounds is close to or better than that of a positive medicine, and the inhibitory effect of the compound 2 used in combination with mistletoe lectin on the joint swelling of the right hind foot of a rat is synergistically enhanced. In summary, the dibenzazepine compound in mistletoe has the potential to be developed into a medicine for treating rheumatoid arthritis, can provide more choices for clinical treatment, and has important social benefits and economic value.

An object is to provide a joint function-improving composition which is useful for prevention or treatment of various arthropathies such as osteoarthritis including knee osteoarthritis as a typical example and rheumatoid arthritis because the composition has an action of promoting growth of chondrocytes and an action of suppressing the production of an inflammation factor, a cartilage matrix degradation factor, a pain factor or a neuronal outgrowth factor by synoviocytes and to provide a joint function-improving product containing the composition such as a food or a drink, feed and a medicine. A joint function-improving composition containing bacterial cells and / or a culture of a bacterium belonging to genera Lactobacillus, Lactococcus, Streptococcus or Bifidobacterium and a joint function-improving agent, a joint function-improving food or drink, a joint function-improving nutritional composition, joint function-improving feed or a joint function-improving pharmaceutical agent which is characterized by containing the joint function-improving composition.

The application discloses application of a medicine composition in preparation of a medicine for treating rheumatoid arthritis (RA), and belongs to the field of RA treating medicines. The medicine composition is composed of swertiamarin (SW) and neochlorogenic acid (NCA) and is screened from two active ingredients in Danteng Yimu Decoction. With the help of animal model and cell model experiments, the action mechanism of the medicine composition in treating RA is explored, the related symptoms and indexes of collagen-induced arthritis (CIA) rats can be effectively improved, joint swelling can be relieved, arthritis inflammation index can be reduced, inflammatory factor release can be inhibited, joint bone quality can be protected, arthritis inflammation infiltration and cartilage destruction can be reduced, and the medicine safety is good. The composition can effectively inhibit the inflammatory factor release and migration ability of rheumatoid arthritis fibroblast-like synoviocytes (RA-FLS). Animal experiments and cell experiments prove that the combination of neochlorogenic acid and swertiamarin (SW+NCA) can be effectively applied to clinical treatment of RA and has a wide application prospect.

The invention discloses a multi-modal data fusion-based rheumatoid arthritis early-stage AI intelligent diagnosis system, belongs to the technical field of medical artificial intelligence, and aims to solve the problems that in the prior art, RA early-stage diagnosis lags behind, the rate of missed diagnosis of serum negative patients is high, and risk assessment lacks quantitative standards. Comprising a multi-source data acquisition module, a data preprocessing module, a cross-modal fusion module, a dynamic time sequence model and a risk assessment module which are connected in sequence, according to the system provided by the invention, a dynamic tracking model of serological change-synovial inflammation-bone structure change is innovatively constructed, and an RA diagnosis window is advanced compared with that of a traditional method (depending on clinical symptoms) by capturing time sequence correlation of the serological change, the synovial inflammation and the bone structure change; aiming at the diagnosis difficulty of serum-negative RA, the system realizes great improvement of diagnosis performance through deep fusion of multi-modal features, serological core indexes, ultrasonic synovial dynamic features and X-ray bone microscopic features.

To provide novel drugs effective in improving pain associated with osteoarthritis of the knee and periarthritis of the shoulder. [Solution] According to the present invention, a synovial pain reliever for arthritis is provided, comprising an endothelin A receptor antagonist as an active ingredient, wherein the arthritis is osteoarthritis of the knee or periarthritis of the shoulder. According to the present invention, it is possible to improve joint pain caused by movements that put a load on the knee joint and joint pain at rest in patients with osteoarthritis of the knee, and it is possible to improve joint pain caused by movements that put a load on the shoulder joint and joint pain at rest in patients with periarthritis of the shoulder.

The application discloses application of myrtenal in preparation of a medicine for preventing and / or treating rheumatoid arthritis. The application verifies for the first time that myrtenal can block the RA inflammatory cascade from multiple aspects, and overcomes the limitation that single-target treatment is easy to produce drug resistance. Specifically, myrtenal can reduce the levels of inflammatory factors and metal proteins; inhibit the proliferation, migration and invasion of synovial fibroblasts SFs; inhibit the expression of glycolysis-related genes, reduce sugar metabolites; inhibit the synovial tissue hyperplasia, inflammatory cell infiltration, bone erosion and bone destruction of mice joints; promote the mental state of arthritis mice to be obviously improved, the food intake to be increased, the hair to be shiny, the joint swelling to be subsided, the bruise of the ankle joint to be subsided, the skin to be improved, and the activity to be sensitive. Therefore, the application proposes a new medical use of myrtenal in treating rheumatoid arthritis, and develops a brand-new therapeutic indication of myrtenal.

The application discloses a kind of nanomedicine for treating rheumatoid arthritis, including triptolide, Y6 fluorescent probe and poloxamer, triptolide and Y6 fluorescent probe are polymerized by poloxamer to form triptolide nanomedicine Y6@TPL, the average particle size of the triptolide nanomedicine Y6@TPL is 20~300nm.The application combines triptolide with Y6 fluorescent probe, constructs a new type of nano delivery system, the system not only realizes the accurate control release of drug, but also can be enhanced by photo-thermal response Targeted accumulation of rheumatoid arthritis lesion site, significantly improve the selective killing effect of triptolide on inflammatory synoviocytes, while greatly reducing the toxic side effects on normal joint tissue.The nano system integrates photo-thermal therapy, photo-thermal imaging and targeted drug delivery functions, and provides an integrated solution for the diagnosis and treatment of RA.

The invention discloses a nano-drug for treating rheumatoid arthritis, the nano-drug comprises triptolide, a Y6 fluorescent probe and poloxamer, the triptolide and the Y6 fluorescent probe are polymerized by the poloxamer to form a triptolide nano-drug Y6 at TPL, and the average particle size of the triptolide nano-drug Y6 at TPL is 20-300 nm. The triptolide and the Y6 fluorescent probe are combined to construct a novel nano delivery system, the system not only realizes precise controlled release of drugs, but also can enhance targeted accumulation of rheumatoid arthritis focus parts through photo-thermal response, the selective killing effect of the triptolide on inflammatory synovial cells is remarkably improved, and the application prospect is broad. Meanwhile, the toxic and side effects on normal joint tissues are greatly reduced. According to the nano system, photo-thermal treatment, photo-thermal imaging and targeted drug delivery functions are integrated, and an integrated solution is provided for diagnosis and treatment of RA.

The invention discloses a Jinhuang powder external application paste and application thereof in preparation of drugs for treating gonitis synovitis, the external application paste is prepared from ten traditional Chinese medicines including turmeric, rheum officinale, golden cypress, radix angelicae, rhizoma arisaematis, pericarpium citri reticulatae, rhizoma atractylodis, mangnolia officinalis, liquorice and radices trichosanthis, honey, edible vegetable oil, paraffin oil and water through a specific emulsification process, the pH value is 6.0-7.0, and the viscosity is 3000-5000 mPa.s; standard random control clinical tests prove that the total effective rate of the external application ointment for treating gonarthromeningitis reaches 99.04%, the Lyshilm score is improved by 30.2 score, the VAS score is reduced by 5.39 score and is greatly superior to that of a diclofenac sodium control group, the adverse reaction occurrence rate is only 3.85%, the levels of serum TNF-alpha, IL-1beta and IL-6 and the synovial thickness can be greatly reduced, and the external application ointment has a good clinical application prospect. The method is suitable for K-L grading I-II and postoperative rehabilitation patients.

This invention discloses the application of PT-129 in the preparation of drugs for treating rheumatoid arthritis (RA), belonging to the field of RA treatment. This invention is the first to demonstrate that the compound PT-129 can target and intervene in the synovial microenvironment, effectively inhibiting the abnormal activation behaviors of RA fibroblast-like synovial cells (FLS) such as proliferation, migration, and invasion, and downregulating the expression of N-cadherin and MMP3 proteins in synovial tissue. This invention provides a combined drug formulation containing PT-129 and RGFP966. This composition exhibits a significant synergistic effect in vivo, effectively relieving joint swelling, increasing bone density and trabecular bone thickness, reducing trabecular bone separation, thereby inhibiting cartilage degradation and bone destruction. This invention provides a novel targeted drug and combination therapy with definite efficacy for the clinical intervention of RA, possessing extremely high clinical application development value.

This invention belongs to the field of pharmaceutical technology, specifically relating to the application of psoralen in the preparation of drugs for the prevention and treatment of rheumatoid arthritis. This invention aims to address the problem of insufficient efficacy and inadequate clinical needs of existing rheumatoid arthritis prevention and treatment drugs, filling the technological gap in the pharmacological activity of psoralen against rheumatoid arthritis. Studies have confirmed that psoralen can effectively inhibit the secretion of IL-6 and IL-8 by RA-FLS cells, effectively inhibit RA-FLS cell proliferation, migration, and invasion, significantly improve joint swelling and weight loss symptoms in CIA mice, effectively regulate immune imbalance, and effectively repair joint pathological damage. It blocks the pathological processes of rheumatoid arthritis, including inflammation, immune disorders, synovial damage, and bone destruction, from multiple pathways and dimensions. Furthermore, psoralen is a natural plant-derived component. This invention provides a novel natural drug option for the treatment of rheumatoid arthritis, effectively improving the existing treatment system for the disease.

The application provides application of SEMA3E protein in preparation of a drug for treating rheumatoid arthritis and promoting cartilage regeneration, and belongs to the technical field of biological medicine. The amino acid sequence of the SEMA3E protein is shown as SEQ ID No. 1. Research results show that one month after injection of the SEMA3E protein solution, the joint swelling degree of the double hind limbs of an animal model is reduced, the joint space and integrity are restored to normal, the cartilage thickness is increased, and the phenomenon of synovial cell infiltration and invasion into the cartilage is eliminated. That is, the SEMA3E protein can well reduce joint cavity inflammation and improve damaged joints.

The application discloses a method for constructing a spontaneous rheumatoid arthritis animal model, and the rheumatoid arthritis phenotype of the mouse is spontaneously generated by knocking out PPARgamma in the skin keratinocytes of the joint part, including joint swelling, joint synovial thickening, inflammatory cell infiltration, anti-cyclic citrullinated polypeptide antibody increase, and rheumatoid factor increase, so that the clinical symptoms of the rheumatoid arthritis are simulated, and an important tool is provided for the related research of the rheumatoid arthritis.

The invention provides application of a composition in treatment of knee osteoarthritis. According to the invention, two rat knee osteoarthritis models (the former is called as an ACLT-induced KOA model for short, and the latter is called as a papain-induced KOA model for short) are established by respectively utilizing methods of combining anterior cruciate ligament transection (ACLT) with running and injecting papain composite L-cysteine into an articular cavity; the composition provided by the invention is used for treating two rat KOA models. Results show that the composition can improve knee joint swelling of two KOA rats, increase the pain threshold, improve the abnormal gait state, relieve cartilage injury, inhibit ACLT-induced abnormal change of a KOA rat knee joint subchondral bone microstructure and papain-induced PGE2 content in KOA rat synovial tissue, and can be used for preparing a medicine for treating osteoporosis. The level of inflammatory factors in serum and joint lavage fluid of the two KOA rats is reduced, and the discovery shows that the KOA has important application in treatment of knee osteoarthritis.

The application discloses a new application of m6A modified gene GAS6 and its receptor MERTK in rheumatoid arthritis. Multi-omics integrated analysis of synovial tissue and peripheral blood mononuclear cells of RA patients reveals common dysregulation of transcriptomics and epitranscriptomics, highlighting genes with both differential expression and m6A modification, which are enriched in processes such as phagocytosis, Th17 differentiation and cell aging. Among these genes, GAS6 shows the most significant m6A hypermethylation and expression up-regulation, and is verified as a key effector molecule interacting with MERTK / AXL receptor. Functional experiments show that GAS6 and MERTK synergistically promote the malignant phenotype of RA fibroblast-like synoviocytes, enhance their proliferation, migration, inflammatory cytokine secretion and anti-apoptotic ability.

The application provides a Chinese medicine composition containing Notopterygium incisum and Lonicera japonica in preparation and treatment of rheumatoid arthritis, and belongs to the technical field of medicine; scientific research shows that the Chinese medicine composition containing Notopterygium incisum and Lonicera japonica can reduce joint cartilage destruction, subchondral bone destruction caused by rheumatoid arthritis, promote osteoblast differentiation and mineralization, reduce joint swelling, synovial hyperplasia, and inflammatory cell infiltration of joints caused by rheumatoid arthritis, has the effect of treating rheumatoid arthritis, and can be developed into a medicine for treating rheumatoid arthritis.

The invention relates to an application of an aromatic acylhydrazone compound or a pharmaceutically acceptable salt thereof in preparation of a medicine for treating rheumatoid arthritis, and an application of the aromatic acylhydrazone compound and methotrexate in preparation of the medicine for treating rheumatoid arthritis. When the aromatic acylhydrazone compound is injected into an articular cavity, the arthritis index score of AA rats can be remarkably reduced, joint symptoms are effectively improved, synovial hyperplasia and cartilage injury are relieved, and TNF-alpha induced RA-FLSs abnormal activation can be remarkably inhibited. Meanwhile, the aromatic acylhydrazone compound disclosed by the invention is combined with methotrexate for use, so that the aromatic acylhydrazone compound has a better effect of treating rheumatoid arthritis and has relatively high clinical application value and development prospect.

Rheumatoid arthritis (RA) is the most common form of inflammatory rheumatism involving small joints which are the seat for swelling and pain with structural damage, responsible for functional disabilities if no treatment is proposed. The inventors show that circulating MAIT cells were reduced and exhibited an activated and anti-apoptotic phenotype in RA patients compared to healthy controls. MAIT cell levels were also found to be increased in the synovial fluid as compared with the peripheral blood, suggesting that circulating MAIT cell deficiency is due to the migration of MAIT cells into the joint. Severity of arthritis induced by mBSA was reduced in mice depleted in MAIT cells. This data suggest that MAIT cells contribute to exacerbation of arthritis. Thus the present invention relates to the use of an agent capable of inhibiting the activation of MAIT cells for the treatment of rheumatoid arthritis

The invention provides a polypeptide for blocking a CRIP1 protein lactic acid process and application of the polypeptide in treatment of rheumatoid arthritis, and belongs to the technical field of biological medicines. The invention provides application of a reagent for blocking CRIP1 protein lactylation in preparation of a medicine for treating rheumatoid arthritis (RA). The invention also specifically designs a functional cell penetrating peptide (CPPs) for treating rheumatoid arthritis, the CPPs can specifically inhibit the lactylation of CRIP1 protein, and has a remarkable treatment effect in cells, synovial explants and animal models, a new theoretical basis is provided for the targeted treatment of synovial fibroblasts, and the application has a wide application prospect. And a potential targeted treatment means is provided for RA patients, and a wide clinical application prospect is achieved.

The present application relates to the field of orthopedic rehabilitation, and in particular to a progressive correction method for rheumatoid arthritis metacarpophalangeal joint ulnar deviation deformity, aiming at the technical pain points of existing correction technology, such as large trauma, poor adaptability, easy secondary synovial membrane injury, high deformity rebound rate, poor function recovery, etc., and combining biological microdynamics, flexible material science, industrial control time sequence regulation and physical rehabilitation technology, a non-invasive time sequence closed loop correction system is constructed. Through the multi-link collaborative implementation of preoperative global accurate evaluation and mechanical anchoring, low-temperature non-inductive fascia targeted pre-loosening, flexible phase change time sequence gradient force, extensor tendon targeted homing linkage, low-frequency micro-vibration microcirculation promotion, active micro-movement compensation balance training, etc., the pathological characteristics of rheumatoid arthritis and the physiological rhythm of the hand are matched throughout the whole process, and there is no rigid compression and surgical trauma. The present application can simultaneously achieve deformity reduction, ligament release, tendon homing, inflammation relief and muscle strength reconstruction, effectively avoid surgical risks and traditional brace complications, and significantly improve the correction success rate.

The invention relates to the technical field of medicines, in particular to application of mulberry total flavonoids in preparation of a preparation for treating rheumatoid arthritis. The medicine mulberry total flavonoids have definite anti-inflammatory and protective effects on the histology level. After intervention of the medicine mulberry general flavone, the autophagy function of the synovial cells can be recovered. The medicine mulberry general flavone can also be used for synchronously down-regulating the expression of p-PI3K, p-AKT and p-mTOR, up-regulating Beclin-1 and LC3-II, and remarkably reducing the levels of TNF-alpha, IL-6 and IL-17 in serum. Therefore, the medicine mulberry general flavone can restore autophagy activity and relieve synovitis and joint injury by inhibiting a PI3K / AKT / mTOR axis.

The invention is applicable to the technical field of traditional Chinese medicine powder for treating arthralgia and provides traditional Chinese medicine powder for treating arthralgia and a preparation method thereof, and the traditional Chinese medicine powder for treating arthralgia comprises the following substances in parts by mass: 8-12 parts of tripterygium wilfordii, 4-6 parts of ligusticum wallichii, 8-12 parts of salvia miltiorrhiza, 1.6-2.4 parts of mirabilite and 4-6 parts of rheum officinale. According to the traditional Chinese medicine steeping powder for treating arthralgia and the preparation method of the traditional Chinese medicine steeping powder, the traditional Chinese medicine steeping powder takes four mechanisms of immunoregulation, anti-inflammation, blood circulation activation and detumescence as a core, accurate strike on the pathological link of rheumatoid arthritis is formed, triptolide in tripterygium wilfordii can inhibit T cell overactivity and block the start of autoimmune response, and the curative effect is good. Ligustrazine improves joint local microcirculation disturbance by expanding microvessels and inhibiting platelet aggregation, tanshinone has a strong anti-oxidation effect and can remove excessive oxygen free radicals generated in the inflammation process and relieve synovial cell damage, and sodium sulfate in mirabilite can promote absorption of inflammatory exudates in articular cavities and relieve swelling.

This invention pertains to the field of medicine and biomedical diagnostics, specifically relating to a method for constructing a rheumatoid arthritis diagnostic classifier and its application. The invention utilizes gene expression profiles associated with rheumatoid arthritis to obtain a dataset for the condition, which includes two subtypes: the matrix subtype C1 and the immune subtype C2. Based on these two subtypes, feature genes are extracted, and a human index RSIMI classifier for the rheumatoid arthritis synovial immune microenvironment is constructed.